Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Bayer AG. (2/8/17). "Press Release: Phase III COMPASS study with Bayer’s Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early []". Berlin.

Organisations Organisation Bayer AG
  Group Bayer (Group)
  Organisation 2 Janssen Research & Development LLC
  Group Johnson & Johnson (JnJ) (Group)
Products Product Xarelto®
  Product 2 clinical research
Person Person Möller, Jörg (BenevolentAI 202401– CEO before Leo Pharma + Bayer 201403–202012)
     


   
Record changed: 2023-06-05

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Bayer (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top